Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Neoplasms 19Stomach Neoplasms 15Colorectal Neoplasms 15Lung Neoplasms 13Endometrial Neoplasms 13Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 10Colonic Neoplasms 9Carcinoma, Hepatocellular 9Oropharyngeal Neoplasms 6Neoplasm Metastasis 6Multiple Myeloma 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Mouth Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Observation × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡